- Sarepta Therapeutics (SRPT -3.1%) falls as Canaccord downgrades the shares to Neutral from Buy.
- "We still predict eventual clinical/commercial success, but feel there is major near-term uncertainty in eteplirsen's regulatory timelines," analyst Ritu Baral notes.
- Long story short: Canaccord likes the DMD treatment's efficacy and safety profile but doesn't necessarily like the confirmatory trial ambiguity.
- Price target is still $20.
Canaccord steps to sidelines on Sarepta
Dec 6 2013, 13:52 ET